The hazard ratio as a measure of effect in clinical trials of elderly populations: common pitfalls and misconceptions

被引:0
|
作者
Stefanos Roumeliotis
Graziella D’Arrigo
Giovanni Tripepi
机构
[1] Aristotle University of Thessaloniki,Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine
[2] Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension,Institute of Clinical Physiology (IFC
[3] Ospedali Riuniti,CNR)
关键词
Hazard ratio; Clinical trials; Risk ratio; Elderly;
D O I
暂无
中图分类号
学科分类号
摘要
The hazard ratio is a measure of effect which is of paramount importance in etiological research, that is in studies aimed at assessing the strength of the causal relationship between a given treatment/exposure and a certain outcome. Despite the widespread use of the hazard ratio as a measure of effect in scientific reports and articles, the interpretation of this index is often accompanied by some misconceptions which can jeopardize the critical appraisal of randomized clinical trials (RCTs) and observational studies as well. Herein, using a series of examples derived from RCTs in the elderly subjects, we address major pitfalls regarding the interpretation of the hazard ratio in geriatric research.
引用
收藏
页码:505 / 511
页数:6
相关论文
共 47 条
  • [41] Effect of vitamin D supplementation on cardiac-metabolic risk factors in elderly: a systematic review and meta-analysis of clinical trials
    Mostafa Qorbani
    Maryam Zarei
    Yousef Moradi
    Geeta Appannah
    Shirin Djalainia
    Kumars Pourrostami
    Hanieh-Sadat Ejtahed
    Armita Mahdavi-Gorabi
    Ebrahim Khalil Naderali
    Maryam Khazdouz
    Diabetology & Metabolic Syndrome, 14
  • [42] Effect of vitamin D supplementation on cardiac-metabolic risk factors in elderly: a systematic review and meta-analysis of clinical trials
    Qorbani, Mostafa
    Zarei, Maryam
    Moradi, Yousef
    Appannah, Geeta
    Djalainia, Shirin
    Pourrostami, Kumars
    Ejtahed, Hanieh-Sadat
    Mahdavi-Gorabi, Armita
    Naderali, Ebrahim Khalil
    Khazdouz, Maryam
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [43] Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations
    Joel L. Young
    Richard N. Powell
    Celeste Zabel
    Jaime Saal
    Lisa L. M. Welling
    Jillian Fortain
    Ashley Ceresnie
    BMC Psychiatry, 23
  • [44] Development and validation of the ADHD Symptom and Side Effect Tracking - Baseline Scale (ASSET-BS): a novel short screening measure for ADHD in clinical populations
    Young, Joel L.
    Powell, Richard N.
    Zabel, Celeste
    Saal, Jaime
    Welling, Lisa L. M.
    Fortain, Jillian
    Ceresnie, Ashley
    BMC PSYCHIATRY, 2023, 23 (01)
  • [45] How to Measure the Effect of Diabetes on Cardiovascular Events during a Clinical Trial? A Meta-analysis of 330,376 Patients from 47 Landmark Trials
    Hermans, Michel P.
    Ahn, Sylvie A.
    Rousseau, Michel F.
    DIABETES, 2015, 64 : A394 - A394
  • [46] Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure"
    Inker, Lesley A.
    Heerspink, Hiddo J. L.
    Vonesh, Edward F.
    Greene, Tom
    CIRCULATION-HEART FAILURE, 2022, 15 (03)
  • [47] Adjuvant treatment in stage III colon cancer:: Comparison of patients recruited into trials and those treated outside a clinical trial:: analysis of recruitment, trial effect and inclusion of elderly patients.
    Rodón, J
    Garcia, M
    Perez, J
    Navarro, M
    Pareja, L
    Germà-Lluch, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 557S - 557S